2,992
回編集
差分
ナビゲーションに移動
検索に移動
Middle East respiratory syndrome (MERS) 中東呼吸器症候群 (ソースを閲覧)
2019年12月23日 (月) 00:42時点における版
、 2019年12月23日 (月) 00:42ページの作成:「{{Quote |content=Modjarrad K, Roberts C, Mills K, et. al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-l…」
{{Quote
|content=Modjarrad K, Roberts C, Mills K, et. al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. The Lancet Infectious Diseases. 2019;19(9):1013-1022. [cited 2019Oct11] Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30266-X/fulltext
}}
{{Collapse
|title=MERSプラスミドワクチン phase 1
|content=
}}
|content=Modjarrad K, Roberts C, Mills K, et. al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. The Lancet Infectious Diseases. 2019;19(9):1013-1022. [cited 2019Oct11] Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30266-X/fulltext
}}
{{Collapse
|title=MERSプラスミドワクチン phase 1
|content=
}}
